20691-71-8

Basic information

• Product Name: 3-amino N,N-dimethyl 4-nitro aniline
• Synonyms: 4-Dimethylamino-1-nitro-2-benzenamine;N,N-Dimethyl-4-nitro-1,3-benzenediamine;(3-Amino-4-nitrophenyl)dimethylamine;5-Dimethylamino-2-nitroaniline;N1,N1-Dimethyl-4-nitro-1,3-benzenediamine;N1,N1-diMethyl-4-nitrobenzene-1,3-diaMine
• CAS NO: 20691-71-8
• Molecular Formula: C₈H₁₁N₃O₂
• Molecular Weight: 181.2
• Mol File: 20691-71-8.mol

Chemical Properties

• Melting Point: 140℃
• Boiling Point: 355℃
• Flash Point: 168℃
• Appearance: /
• Density: 1.280
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 0.75±0.22(Predicted)
• CAS DataBase Reference: 3-amino N,N-dimethyl 4-nitro aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino N,N-dimethyl 4-nitro aniline(20691-71-8)
• EPA Substance Registry System: 3-amino N,N-dimethyl 4-nitro aniline(20691-71-8)

Safety Data

• Hazardous Substances Data: 20691-71-8(Hazardous Substances Data)

Usage

Uses

Used in Dye and Pigment Industry:
3-amino N,N-dimethyl 4-nitro aniline is used as a chemical intermediate for the synthesis of dyes and pigments, contributing to the coloration and stability of these products in various applications.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 3-amino N,N-dimethyl 4-nitro aniline is utilized as a precursor in the production of certain medications, playing a vital role in the development of new drugs.
Used in Agrochemical Industry:
3-amino N,N-dimethyl 4-nitro aniline is employed as a component in the manufacturing process of agrochemicals, aiding in the creation of products designed to protect and enhance crop yields.

Upstream product

• 2369-11-1 5-fluoro-2-nitroaniline 
• 506-59-2 N,N-dimethylammonium chloride 
• 1635-61-6 5-chloro-2-nitroaniline 
• 124-40-3 dimethyl amine 
• 121-69-7 N,N-dimethyl-aniline 
• 345-14-2 N-methylcarbonyl 2-nitro-5-fluoroaniline 
• 35998-95-9 N,N-dimethyl-3,4-dinitroaniline 
• 7664-41-7 ammonia 
• 68-12-2 N,N-dimethyl-formamide 
• 109-01-3 1-methyl-piperazine 
• 129195-09-1 5-(N,N-dimethylamino)-2-nitroacetamide 
• 110-91-8 morpholine 
• 5228-61-5 5-bromo-2-nitroaniline 

Downstream Products

• 63019-99-8 4-dimethylamino-2-(phenylamino)nitrobenzene 
• 1339046-25-1 2-amino-4-(5'-(dimethylamino)benzimidazol-2'-yl)aniline 
• 1339046-23-9 4-(5'-(dimethylamino)benzimidazol-2'-yl)-2-nitroaniline 
• 1262887-26-2 N,N-dimethyl-1H-benzo[d]imidazol-6-amine 
• 6124-22-7 5-Dimethylamino-benzofurazan 
• 63019-87-4 acetic acid-(2-anilino-4-dimethylamino-anilide) 
• 53666-59-4 2-Chlor-N⁴,N⁴-dimethyl-p-phenylendiamin 
• 152601-80-4 (E)-3-(p-13-aza-1,4,7,10-tetraoxacyclopentadecane-13-ylstyryl)-7-(N,N-dimethylamino)-1,4-benzodiazine-2-one 
• 889664-44-2 1-[5-N,N-dimethylamino-2-(2-quinolinyl)benzimidazole]-1'-α-deoxyriboside-5'-O-(4,4'-dimethoxytrityl) ether-3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite 
• 889664-42-0 1-[5-N,N-dimethylamino-2-(2-pyridinyl)benzimidazole]-1'-α-deoxyriboside-5'-O-(4,4'-dimethoxytrityl) ether-3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) 
• 889664-43-1 1-[5-N,N-dimethylamino-2-(2-quinolinyl)benzimidazole]-1'-α-deoxyriboside-5'-O-(4,4'-dimethoxytrityl) ether 
• 909777-15-7 C₃₉H₃₆N₄O₅ 
• 889664-41-9 1-[5-N,N-dimethylamino-2-(2-pyridinyl)benzimidazole]-1'-α-deoxyriboside-5'-O-(4,4'-dimethoxytrityl) ether 
• 42197-31-9 Dimethyl-[2-(4-nitro-phenyl)-1H-benzoimidazol-5-yl]-amine 

Relevant articles and documents

Synthesis and characterization of 8-aminoquinolines, substituted by electron donating groups, as high-affinity copper chelators for the treatment of Alzheimer's disease

The deregulation of copper homeostasis generates copper–amyloid aggregation and strongly participates in neuron damage in the brains of patients with Alzheimer's disease. Therefore, copper chelators able to regulate copper homeostasis should be considered

Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents

In this study, three pairs of optically pure 18F-labeled 2-phenylquinoxaline derivatives were evaluated as Tau imaging agents for the diagnosis of Alzheimer's disease (AD). The chiral 2-fluoromethyl-1,2-ethylenediol side chain was attached to the 2-phenyl

Pyrazole spleen tyrosine kinase inhibitor as well as preparation method and application thereof

The invention discloses a pyrazole spleen tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical composition containing the same, and application of the pyrazole spleen tyrosine kinase inhibitor and the pharmaceutical composition in the preparation of drugs for treating Syk-mediated diseases including cancers, inflammatory diseases and the like.

2 -aryl quinoxaline compound with affinity with Tau protein as well as preparation method and application thereof (by machine translation)

The invention provides 2 -arylquinoxaline compounds with affinity with Tau protein, and the structure is as shown in a formula (I). The invention further provides a preparation method of the compound of the formula (I). The compound can be directly used a

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

Interaction of bisbenzimidazole-substituted carbazole derivatives with G-quadruplexes and living cells

G-quadruplex (G4) ligands have potential as chemotherapeutic agents because of the important roles of G4s in regulation of genomic function. Previously, we have developed a fluorescent probe (termed as BPBC) with excellent selectivity to parallel G4s, which possesses a V-shaped bisbenzimidazole-substituted carbazole planar core and two methylpiperazine side arms. Here, we further investigated the interactions of BPBC derivatives with different DNA and living cells. The spectral analysis showed that non-substituted bisbenzimidazole-substituted carbazole (7c) and bisdimethylamino-substituted 7c (7b) exhibited good selectivity to parallel G4s. The binding affinities of BPBC derivatives to parallel G4s were BPBC > 7b 7c. BPBC and 7b entered living cells and mainly located in the cytoplasma and nucleoli; 7c mainly located in the lysosome. BPBC exhibited the highest cytotoxicity with IC50 around 1 μM. Our results suggest that the bisbenzimidazole-substituted carbazole core is the key factor for selectively binding BPBC derivatives to parallel G4s; the side arms can change their affinity to specific G4s, as well as their interaction with cells. Further optimization of the side arms will provide the opportunity to obtain chemotherapeutic agents targeting specific G4s in cells.

RADIOPROTECTOR COMPOUNDS AND METHODS

The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection). Preferred compounds of the invention are those of Formula (II), as follows: wherein W represents -N(R1R2) where R1 and R2 are not both hydrogen and where they may together form a 5, 6 or 7 membered ring structure, -NHN(R1R2), NHR3N(R1R2), -NHR3OR2, -N(R3)R3OR2, -N(R1)R3OR3OR3, OR3NR1R2, -OR3 or W represents piperidyl, piperazinyl, morpholinyl, thiomorpholinyl or diazepanyl each of which may be optionally substituted by C1 to C4 alkyl, C2 to C4 alkenyl, -N(CO)N(R1R2), -N(CO)OR1, -N(CO)OR3OH, -(CO)NR1R2, -R3(CO)NR1R2, -R3OR1, -OR1, -N(R1R2) OR -NH-; R1 and R2 are the or different and are selected from hydrogen, C1 to C4 alkyl or C2 to C4 alkenyl; group or chain; Z is the same or different and represents N or CH; Z' is the same or different and represents N or C; X represents CH, N or NH, where .. is a double bond when X is CH or N and a single bond when X is NH; X' represents N or NH, wherein when X is CH or N X' is NH and wherein X and X' are different and further where ～～～is a double bond when X' is N and a single bond when X' is NH; Q represents H, alkoxyl, -NR1R2, F or Cl; Q1 is absent when Z' is N and when Z' is C it represents H, alkoxyl, -NR1R2, F or Cl; A represents a five to ten membered single or multiple ring structure with heterocyclic N or O located at the ortho position, said ring including optional double bonds, substitutions and/or other heteroatoms and pharmaceutically acceptable derivatives thereof.

Sensing metal ions with DNA building blocks: Fluorescent pyridobenzimidazole nucleosides

We describe novel fluorescent N-deoxyribosides (1 and 2) having 2-pyrido-2-benzimidazole and 2-quino-2-benzimidazole as aglycones. The compounds were prepared from the previously unknown heterocyclic precursors and Hoffer's chlorosugar, yielding alpha ano

MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.